1. 176P Phase I study of INCB106385 alone or in combination with immunotherapy in advanced solid tumors. (December 2022) Authors: Italiano, A.; Saavedra Santa Gadea, O.; Papadopoulos, K.; Naing, A.; Gomez-Roca, C.A.; Mita, M.; Stein, M.; Rybicka, I.; van der Velden, M.; Zhang, P.; Smith, M.; Ivanova, O.; Loriot, Y. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 31LBA MOST – My Own Specific Therapy – A multicenter, randomized, open-label, phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors: preliminary results from the everolimus and sorafenib cohorts. (September 2015) Authors: Toulmonde, M.; Le Tourneau, C.; Cropet, C.; Italiano, A.; Bertucci, F.; Ray-Coquard, I.; Tredan, O.; Cassier, P.; Seigne, C.; De la Fouchardiere, C.; Flechon, A.; Desseigne, F.; Frappaz, D.; Gomez-Roca, C.A.; Heudel, P.E.; You, B.; Jaouen, L.; Bernardin, M.; Perol, D.; Blay, J.Y. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S725 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗